Paola Guglielmelli

Nano-GLADIATOR: real-time detection of copy number alterations from nanopore sequencing data

Alberto Magi, Davide Bolognini, Niccoló Bartalucci, 2019, Bioinform..

Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia.

Paola Guglielmelli, Giovanni Barosi, Roberto Marchioli, 2007, Blood.

Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms

Paola Guglielmelli, Torsten Haferlach, William Tapper, 2015, Nature Communications.

Effect of mutation order on myeloproliferative neoplasms.

Paola Guglielmelli, George S Vassiliou, Beatriz Bellosillo, 2015, The New England journal of medicine.

JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis.

Paola Guglielmelli, Giovanni Barosi, Carmine Tinelli, 2007, Blood.

Molecular Profiling of CD34+ Cells in Idiopathic Myelofibrosis Identifies a Set of Disease‐Associated Genes and Reveals the Clinical Significance of Wilms' Tumor Gene 1 (WT1)

Francesco Mannelli, Paola Guglielmelli, Giovanni Barosi, 2007, Stem cells.